[go: up one dir, main page]

PL3722808T3 - Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam - Google Patents

Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam

Info

Publication number
PL3722808T3
PL3722808T3 PL20162844.3T PL20162844T PL3722808T3 PL 3722808 T3 PL3722808 T3 PL 3722808T3 PL 20162844 T PL20162844 T PL 20162844T PL 3722808 T3 PL3722808 T3 PL 3722808T3
Authority
PL
Poland
Prior art keywords
differences
svcam
alpha
methods
correlating
Prior art date
Application number
PL20162844.3T
Other languages
English (en)
Inventor
Alissa A. Chackerian
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of PL3722808T3 publication Critical patent/PL3722808T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL20162844.3T 2010-10-25 2011-10-24 Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam PL3722808T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40636510P 2010-10-25 2010-10-25
US40635810P 2010-10-25 2010-10-25

Publications (1)

Publication Number Publication Date
PL3722808T3 true PL3722808T3 (pl) 2025-02-03

Family

ID=46024768

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20162844.3T PL3722808T3 (pl) 2010-10-25 2011-10-24 Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam
PL17192860T PL3326645T3 (pl) 2010-10-25 2011-10-24 Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17192860T PL3326645T3 (pl) 2010-10-25 2011-10-24 Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM

Country Status (19)

Country Link
US (3) US20130337470A1 (pl)
EP (3) EP2632492B1 (pl)
JP (2) JP5847188B2 (pl)
AU (4) AU2011323820A1 (pl)
CA (1) CA2816016A1 (pl)
CY (1) CY1123060T1 (pl)
DK (2) DK3326645T3 (pl)
ES (3) ES2997080T3 (pl)
FI (1) FI3722808T3 (pl)
HK (1) HK1256157A1 (pl)
HR (2) HRP20241666T1 (pl)
HU (1) HUE050713T2 (pl)
LT (2) LT3326645T (pl)
PL (2) PL3722808T3 (pl)
PT (2) PT3722808T (pl)
RS (2) RS60565B1 (pl)
SI (2) SI3326645T1 (pl)
SM (2) SMT202000380T1 (pl)
WO (1) WO2012061074A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3722808T3 (pl) 2010-10-25 2025-02-03 Biogen Ma Inc. Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam
JP2018504584A (ja) * 2014-12-02 2018-02-15 ネステク ソシエテ アノニム 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5338689A (en) 1987-08-24 1994-08-16 Stiftung Fur Diagnostische Forschung Method and card for detecting antigens and/or antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
BE1008817A6 (fr) 1994-10-28 1996-08-06 Univ Bruxelles Procede d'obtention d'adn bicatenaire membranaire humain, produit obtenu par ce procede et trousse de diagnostic le contenant.
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
US5965356A (en) 1997-01-31 1999-10-12 University Of Maryland, Baltimore Herpes simplex virus type specific seroassay
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
EP1078006B1 (en) * 1998-05-13 2009-03-04 Genentech, Inc. Diagnosis and treatment of hepatic disorders
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
BR0016818A (pt) 1999-12-28 2002-10-01 Pfizer Prod Inc Inibidores não-peptidila de adesão celular dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias
JP5113314B2 (ja) * 2000-09-01 2013-01-09 ザ センター フォー ブラッド リサーチ インク 所望のコンホメーションで安定させた改変ポリペプチド及び該ポリペプチドの作製方法
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PT2336184E (pt) 2002-02-25 2015-03-09 Biogen Idec Inc Administração de agentes para o tratamento da inflamação
PE20040942A1 (es) 2003-01-24 2004-12-28 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes
SI3417875T1 (sl) 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
EP1718310A4 (en) 2004-02-06 2009-05-06 Elan Pharm Inc METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
AU2005231467A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
AR054233A1 (es) 2005-03-08 2007-06-13 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos igg2
SI3264094T1 (sl) * 2005-04-04 2021-04-30 Biogen Ma Inc. Metode za ocenjevanje imunskega odziva na terapevtsko učinkovino
PL2676967T3 (pl) 2006-02-28 2019-12-31 Biogen Ma Inc. Metody leczenia chorób zapalnych i autoimmunologicznych za pomocą natalizumabu
AU2007224228B2 (en) 2006-03-03 2013-09-19 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
JP2011506322A (ja) 2007-12-07 2011-03-03 エラン ファーマシューティカルズ，インコーポレイテッド 液性腫瘍を治療するための方法および組成物
US20100255508A1 (en) * 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2009141786A2 (en) 2008-05-21 2009-11-26 Piramal Life Sciences Limited Anti-inflammatory compounds
WO2010053316A2 (en) 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
CN102883750A (zh) * 2010-04-30 2013-01-16 伊兰药品公司 选择性整联蛋白抑制剂
PL3722808T3 (pl) 2010-10-25 2025-02-03 Biogen Ma Inc. Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam

Also Published As

Publication number Publication date
SMT202400498T1 (it) 2025-01-14
HUE050713T2 (hu) 2020-12-28
ES2997080T3 (en) 2025-02-14
AU2011323820A1 (en) 2013-05-23
AU2017201658A1 (en) 2017-03-30
SI3326645T1 (sl) 2020-09-30
EP3722808B1 (en) 2024-09-11
JP2015215363A (ja) 2015-12-03
HRP20241666T1 (hr) 2025-02-14
PT3722808T (pt) 2024-12-09
AU2021212059A1 (en) 2021-08-26
ES2800066T3 (es) 2020-12-23
JP5847188B2 (ja) 2016-01-20
ES2654820T3 (es) 2018-02-15
LT3326645T (lt) 2020-08-10
PL3326645T3 (pl) 2020-09-21
CY1123060T1 (el) 2021-10-29
RS60565B1 (sr) 2020-08-31
US20130337470A1 (en) 2013-12-19
DK3722808T3 (da) 2024-12-09
RS66261B1 (sr) 2024-12-31
FI3722808T3 (fi) 2024-12-10
US20160291035A1 (en) 2016-10-06
LT3722808T (lt) 2024-12-27
WO2012061074A1 (en) 2012-05-10
PT3326645T (pt) 2020-06-23
AU2017201658B2 (en) 2019-03-21
EP2632492A4 (en) 2014-04-02
DK3326645T3 (da) 2020-06-15
EP2632492B1 (en) 2017-10-04
US11079393B2 (en) 2021-08-03
SI3722808T1 (sl) 2025-02-28
EP3326645A1 (en) 2018-05-30
EP2632492A1 (en) 2013-09-04
AU2019204089A1 (en) 2019-07-04
AU2021212059B2 (en) 2025-02-27
JP2014500950A (ja) 2014-01-16
EP3722808A1 (en) 2020-10-14
HRP20200920T1 (hr) 2020-10-30
US20220206012A1 (en) 2022-06-30
EP3326645B1 (en) 2020-03-18
CA2816016A1 (en) 2012-05-10
SMT202000380T1 (it) 2020-09-10
HK1256157A1 (zh) 2019-09-13

Similar Documents

Publication Publication Date Title
HK1232292A1 (zh) 樣品使用最大化的系統和方法
EP2700061A4 (en) SYSTEMS AND METHOD FOR ANALYZING ENERGY CONSUMPTION
HK1193471A1 (zh) 識別和測量網狀細胞
HK1206065A1 (en) Compositions and methods for analyte detection
GB2516204B (en) Multi-cue object detection and analysis
EP2456361A4 (en) SYSTEMS FOR CONTINUOUS ANALYTING MEASUREMENT AND SYSTEMS AND METHOD FOR THE IMPLEMENTATION THEREOF
SG11201401913YA (en) Systems and methods for biological analysis
EP2663864A4 (en) IMMUNODIVERSITY QUICK PROCEDURE AND ITS APPLICATION
SG11201401956XA (en) Undifferentiated cell detection method and complex carbohydrate detection method
EP2788794A4 (en) PERMEABILITY PREDICTION SYSTEMS AND METHODS INVOLVING QUADRATIC DISCRIMINANT ANALYSIS
IL222752A0 (en) Acoustic methods and systems for detecting terahertz radioation
EP2705135A4 (en) SYSTEMS AND METHODS FOR ANALYZING BASOPHILES
ZA201208522B (en) Methods for measuring enzyme activity useful in determining cell viability in non-purified sapmles
EP2612256A4 (en) IMPLEMENTATION OF »WHAT-IF-ANALYSIS
EP2553115A4 (en) METHODS OF CULTURE AND ANALYSIS OF CELLS
SG11201401911XA (en) Systems and methods for biological analysis
EP2726813A4 (en) SURFACE MEASURING SYSTEM AND METHOD
EP2693195A4 (en) SPR SENSOR CELL, AND SPR SENSOR
EP2576809A4 (en) MEASURE A YEAST CONCENTRATION AND LIFE CAPABILITY
EP2567215A4 (en) ANALYSIS AGENTS AND METHOD THEREFOR
EP2640407A4 (en) PROCESS FOR INCREASING THE EXPRESSION AND ACTIVITY OF NEPRILYSIN
EP2612257A4 (en) SYSTEMS AND METHODS FOR ANALYZING DOCUMENTS
GB201207583D0 (en) Electrochemical detection method and related aspects
EP2790033A4 (en) GAP PROCESS AND DEVICE, AND MOLDING DEVICE WITH INSTALLED GAP MEASUREMENT DEVICE
EP2757363A4 (en) PLASMON SURFACE RESONANCE SENSOR CELL (SPR) AND SPR SENSOR